

**Chloramine-T (trihydrate) & *p*-Toluenesulfonamide**  
CAS #s 7080-50-4, 127-65-1 & 70-55-3

**ORAL RISK ASSESSMENT DOCUMENT**



**NSF International**  
**Ann Arbor, Michigan**  
**Fall 2018**

## TABLE OF CONTENTS

1.0	INTRODUCTION .....	7
2.0	PHYSICAL AND CHEMICAL PROPERTIES .....	9
2.1	Organoleptic Properties .....	11
3.0	PRODUCTION AND USE.....	11
3.1	Production .....	11
3.2	Use .....	12
4.0	ANALYTICAL METHODS .....	12
4.1	Analysis in Water.....	12
4.2	Analysis in Biological Matrices.....	13
5.0	SOURCES OF HUMAN AND ENVIRONMENTAL EXPOSURE.....	13
5.1	Sources of Human Exposure.....	13
5.2	Sources of Environmental Exposure.....	14
6.0	COMPARATIVE KINETICS AND METABOLISM IN HUMANS AND LABORATORY ANIMALS.....	14
6.1	Absorption .....	15
6.2	Distribution.....	16
6.3	Metabolism .....	16
6.4	Elimination/Excretion.....	18
6.5	Conclusions Regarding Comparative Kinetics and Metabolism.....	18
7.0	EFFECTS ON HUMANS.....	19
7.1	Case Reports.....	20
7.2	Epidemiological Studies.....	21
8.0	EFFECTS ON LABORATORY ANIMALS AND <i>IN VITRO</i> TEST SYSTEMS .....	22
8.1	Limited-Exposure Effects.....	22
8.1.1	<i>Dermal Irritation and Sensitization Studies.....</i>	<i>23</i>
8.1.2	<i>Ocular Exposure Studies .....</i>	<i>24</i>
8.2	Single-Exposure Studies .....	25
8.3	Short-Term Exposure Studies .....	25
8.4	Long-Term and Chronic Exposure Studies.....	28
8.5	Studies of Genotoxicity and Related End-Points .....	33
8.6	Reproduction and Developmental Toxicity Studies.....	39
8.7	Studies of Immunological and Neurological Effects .....	42

<b>9.0</b>	<b>RISK CHARACTERIZATION</b> .....	<b>42</b>
<b>9.1</b>	<b>Hazard Assessment</b> .....	<b>43</b>
9.1.1	<i>Evaluation of Major Non-Cancer Effects and Mode of Action</i> .....	44
9.1.2	<i>Weight-of-Evidence Evaluation and Cancer Characterization</i> .....	48
9.1.3	<i>Selection of Key Study and Critical Effect</i> .....	49
9.1.4	<i>Identification of Susceptible Populations</i> .....	50
<b>9.2</b>	<b>Dose-Response Assessment</b> .....	<b>50</b>
9.2.1	<i>Dosimetric Scaling</i> .....	50
9.2.2	<i>Comparative Points of Departure</i> .....	50
9.2.3	<i>Uncertainty Factor Selection</i> .....	51
9.2.4	<i>Oral RfD Calculation</i> .....	52
<b>9.3</b>	<b>Exposure Assessment</b> .....	<b>52</b>
<b>9.4</b>	<b>TAC Derivation</b> .....	<b>53</b>
<b>9.5</b>	<b>STEL Derivation</b> .....	<b>53</b>
9.5.1	<i>Uncertainty Factor Selection</i> .....	54
9.5.2	<i>STEL Calculation</i> .....	54
<b>10.0</b>	<b>RISK MANAGEMENT</b> .....	<b>54</b>
<b>10.1</b>	<b>SPAC Derivation</b> .....	<b>54</b>
<b>11.0</b>	<b>RISK COMPARISONS AND CONCLUSIONS</b> .....	<b>54</b>
<b>12.0</b>	<b>REFERENCES</b> .....	<b>56</b>
<b>13.0</b>	<b>APPENDICES</b> .....	<b>64</b>
13.1	<b>Uncertainty Factor Selection Criteria</b> .....	64
13.2	<b>ToxRTool Reliability Assessment for Key Study (90-day feeding study in rats for chloramine-T trihydrate)</b> .....	66
13.3	<b>Study Summaries</b> .....	68
<b>14.0</b>	<b>PEER REVIEW HISTORY</b> .....	<b>72</b>

## AUTHORS, PEER REVIEWERS, AND ACKNOWLEDGEMENTS

### **Author:**

Kelly A Magurany, M.Sc., DABT  
Principal Research Toxicologist  
NSF International  
789 Dixboro Road  
Ann Arbor, MI 48105  
1.800.NSF.MARK

### **Disclaimer:**

The responsibility for the content of this document remains solely with NSF International, and the author noted above should be contacted with comments or for clarification. Mention of trade names, proprietary products, or specific equipment does not constitute an endorsement by NSF International, nor does it imply that other products may not be equally suitable.

### **Internal Peer Reviewers:**

Kevin D. Cox, MPH JD

### **External Peer Reviewers:**

NSF International gratefully acknowledges the efforts of the following experts on the NSF Health Advisory Board in providing peer review. These peer reviewers serve on a voluntary basis, and their opinions do not necessarily represent the opinions of the organizations with which they are affiliated.

Edward Ohanian, Ph.D. (Chair, NSF Health Advisory Board)  
Associate Director for Science  
Office of Water  
U.S. Environmental Protection Agency

Helen M. Goeden, Ph.D. (Vice Chair, NSF Health Advisory Board)  
Epidemiologist - Principal Toxicologist  
Minnesota Department of Health  
State of Minnesota

David Blakey, D.Phil.  
Director, Environmental Health Science and Research Bureau  
Safe Environments Programme  
Health Canada (retired)

Steven Bursian, Ph.D.  
Professor  
Michigan State University

Caroline English, Ph.D., DABT  
Independent Consultant

Craig Farr, Ph.D., DABT, Fellow ATS  
Consultant  
Craig Farr Consulting, LLC  
Elaine Z. Francis, Ph.D.  
President  
Sandcastle Toxicology Associates

Lynne Haber, Ph.D., DABT  
Senior Toxicologist/Adjunct Associate Professor  
Department of Environmental Health  
College of Medicine  
University of Cincinnati

Robert Hinderer, Ph.D.  
Robert Hinderer Consulting, LLC

John C. Lipscomb, PhD, DABT, ATS  
Toxicologist  
National Homeland Security Research Center  
U.S. Environmental Protection Agency

Ernest E. McConnell, D.V.M., DACVP, DABT  
ToxPath, Inc.

## EXECUTIVE SUMMARY

Chloramine-T (CAS#s 7080-50-4 (trihydrate), 127-65-1) & *p*-TSA (CAS# 70-55-3)– Oral Risk Assessment

PARAMETER	LEVEL	UNITS	DERIVED
<b>NOAEL</b> (no-observed-adverse-effect level)	30	mg/kg-day	From a 90-day oral feeding study for chloramine-T trihydrate in rats
<b>NOAEL<sub>HED</sub></b> (NOAEL oral human equivalent dose)	5.8	mg/kg-day	Adjusted using BW <sup>3/4</sup> due to lack of relevant chemical-specific toxicokinetic data (as anhydrous chloramine-T)
<b>Oral RfD</b> (oral reference dose)	0.02	mg/kg-day	From a 90-day feeding study in rats, with an uncertainty factor of 300 (as anhydrous chloramine-T)
<b>TAC</b> (total allowable concentration)	0.1	mg/L	For a 70 kg adult drinking two L/day using a 20% relative source contribution for drinking water
<b>SPAC</b> (single product allowable concentration)	0.1	mg/L	Equivalent to TAC as directly added to water for disinfection purposes (outside of U.S.)
<b>STEL</b> (short term exposure level)	2	mg/L	From a 28-day study of chloramine-T trihydrate in rats with a LOAEL of 300 mg/kg-day
<b>EXPOSURE SUMMARY</b>	Chloramine-T (in trihydrate form) is a disinfectant with water uses limited to aquaculture (globally) and emergency water treatment (outside the U.S.). It may be used as a chemical intermediate in food processing and as disinfectant in dental, medicinal, and veterinary applications. <i>p</i> -TSA is the degradant of disinfection and primary metabolite of chloramine-T. <i>p</i> -TSA is used in chemical synthesis, industrial applications, in food contact adhesives, and in investigational medicine. Exposure results from oral, dermal, and inhalation routes.		
<b>KEY STUDY</b>	90-day oral toxicity of chloramine-T trihydrate in Wistar rats. (1971 TNO study summary by ECHA, 2018)		
<b>CRITICAL EFFECT</b>	Statistically significant increased relative kidney weights in male and female rats with increased incidence of calcareous deposits in the kidneys of female rats		
<b>UNCERTAINTY FACTORS</b>	<p>Factors applied in calculating the oral RfD include:</p> <ul style="list-style-type: none"> <li>• <b>3x</b> for interspecies extrapolation</li> <li>• <b>10x</b> for intraspecies extrapolation</li> <li>• <b>10x</b> for subchronic to chronic extrapolation</li> </ul> <p>The total uncertainty factor is therefore <b>300x</b>.</p>		
<b>TOXICITY SUMMARY</b>	<p>Human occupational exposure studies and case reports indicate risk of occupational asthma and dermal sensitization from exposure to chloramine-T disinfectant products. Chloramine-T powders and concentrated solutions are considered irritating. Chloramine-T and <i>p</i>-TSA are of moderate acute toxicity with oral LD50 values ranging from 381.6 to 4700 mg/kg in the rat, mouse, and rabbit. Rapid absorption and metabolism of chloramine-T leads to formation of <i>p</i>-toluenesulfonamide (<i>p</i>-TSA) upon ingestion, which is subsequently partially oxidized to 4-sulphamoylbenzoic acid and excreted primarily in the urine. Complete elimination occurs within 5 days of oral exposure. Chloramine-T has shown no mutagenic activity in bacterial reverse mutation assays with or without metabolic activation. <i>p</i>-TSA has given positive results in tester strain TA98 with metabolic activation; however, several subsequent, guideline compliant, independent, replicates with TA98 were negative. Additional relevant <i>in vivo</i> assays were negative. Based on the lack of guideline compliant carcinogenicity studies in humans or animals, it is concluded that there is “<i>Inadequate Information to Assess Carcinogenic Potential</i>” according to US EPA guidelines (2005). 28-day and 90-day feeding studies in rats were available for chloramine-T (trihydrate). The 28-day study resulted in a LOAEL of 300 mg/kg-day with increased relative kidney and liver weights observed at all dose levels and in both sexes. Increased relative kidney weights in both sexes and increased incidence of calcareous deposits in kidneys of female rats were reported at 100 mg/kg-day in the 90-day study, resulting in a NOAEL of 30 mg/kg-day. Four additional 90-day feeding studies were available for <i>p</i>-TSA in rats, mice, and dogs, with NOAELs ranging from 30 – 780 mg/kg-day. Reproductive and developmental toxicity studies were available only for <i>p</i>-TSA and a single developmental study for chloramine-T, with indication for adverse effects co-occurring with maternal toxicity (reduced body weights in dams and offspring; increased fetal mortality, increased post-implantation losses and resorption rates, and at high exposure level delayed balanopreputial separation and vaginal opening). No teratogenic effects were observed other than vertebral anomalies in one rabbit study that was correlated with reduced fetal body weight. The lowest LOAEL from these studies was 65 mg/kg.</p>		
<b>CONCLUSIONS</b>	Based on a quantitative approach utilizing the available guideline-compliant or robust study summaries available from multiple regulatory authority reviews for chloramine-T and <i>p</i> -TSA, these drinking water action levels are protective of public health.		

## 1.0 INTRODUCTION

This document has been prepared to allow toxicological evaluation of the unregulated disinfectant chloramine-T and its primary degradant and metabolite, *p*-toluenesulfonamide, in drinking water, as drinking water treatment chemicals evaluated under NSF/ANSI 60 (2017). Both non-cancer and cancer endpoints have been considered, and risk assessment methodology developed by the U.S. Environmental Protection Agency (U.S. EPA) has been used.

Non-cancer endpoints are evaluated using the reference dose (RfD) approach (Barnes and Dourson, 1988; Dourson, 1994; U.S. EPA, 1993; U.S. EPA, 2002), which assumes that there is a threshold for these endpoints that will not be exceeded if appropriate uncertainty factors (Dourson et al., 1996; U.S. EPA, 2002; WHO/IPCS, 2005) are applied to the highest dose showing no significant effects. This highest dose is derived from human exposure data when available, but more often is derived from studies in laboratory animals. Either the no-observed-adverse-effect level (NOAEL) taken directly from the dose-response data, or the calculated lower 95% confidence limit on the dose resulting in an estimated 10% increase in response (the LED<sub>10</sub> or BMDL<sub>10</sub> from benchmark dose programs) can be used (U.S. EPA, 2017). The lowest-observed-adverse-effect level (LOAEL) can also be used, with an additional uncertainty factor, although the benchmark dose approach is preferred in this case. The RfD is expressed in mg/kg-day. It is defined by the U.S. EPA as “an estimate (with uncertainty spanning perhaps an order of magnitude) of a daily exposure to the human population (including sensitive subgroups) that is likely to be without an appreciable risk of deleterious effects during a lifetime” (Barnes and Dourson, 1988; U.S. EPA, 1993; U.S. EPA, 2011a).

NSF International uses the RfD to derive three product evaluation criteria for non-cancer endpoints. The total allowable concentration (TAC), generally used to evaluate the results of extraction testing normalized to static at-the-tap conditions, is defined as the RfD multiplied by the 70 kg weight of an average adult assumed to drink two liters of water per day. A relative source contribution (RSC), to ensure that the RfD is not exceeded when food and other non-water sources of exposure to the chemical are considered, is also applied in calculating the TAC. The relative source contribution should be data derived, if possible. Alternately, a 20% default contribution for water can be used (U.S. EPA, 1991a). The TAC calculation is then as follows:

$$\text{TAC (mg/L)} = \frac{[\text{RfD (mg/kg-day)} \times 70 \text{ kg}] - [\text{total contribution of other sources (mg/day)}]}{2 \text{ L/day}}$$

or

$$\text{TAC (mg/L)} = \frac{\text{RfD (mg/kg-day)} \times 70 \text{ kg}}{2 \text{ L/day}} \times 0.2 \text{ (RSC)}$$

The single product allowable concentration (SPAC), used for water treatment chemicals and for water contact materials normalized to flowing at-the-tap conditions, is the TAC divided by the estimated total number of sources of the substance in the drinking water treatment and distribution system. In the absence of source data, a default multiple source factor of 10 is used. This accounts for the possibility that more than one product in the water and/or its distribution system could contribute the contaminant in question to drinking water.